Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 04 August 2006
Grant support for cancer immunotherapy
programmes
Oxford BioMedica had been awarded a grant of more than £900,000 to support its immunotherapy programme
The award was made in February 2003 by the UK Department of Trade and Industry under the pan-European Eureka initiative Oxford BioMedica received the award following its recently announced collaboration with Intervet SA to develop TroVax-VET for the treatment of cancer in companion animals
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
The grant is to support Oxford BioMedica's development of a broad range of applications for 5T4, its proprietary tumour-associated antigen.
5T4 is the active immunogenic component of the company's lead cancer product TroVax, which is entering a number of Phase II clinical trials this year.
In addition, an antibody against 5T4 is the subject of Oxford BioMedica's immunotoxin collaboration with Wyeth, a deal worth $24 million in upfront and milestone payments.
Eureka is a pan-European network for market-oriented, industrial R+D.
Eureka supports the competitiveness of European companies through international collaboration, in creating links and networks of innovation.
The objective is to bring high quality research and development efforts to the market and to use the multiplying effects of co-operation.
The aim is to advance and improve the quality of life.
Commenting on the award of this grant, Oxford BioMedica's CEO, professor Alan Kingsman said: "It is particularly pleasing to receive a substantial grant from the DTI following substantial peer review of our technology and product rationale.
"This provides a very strong external endorsement of the technical and commercial potential of BioMedica's immunotherapy programme.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
